Award
National Institute on Drug Abuse RFA-DA-23-021
Cue-induced drug craving monitoring for opioid use disorder with visual evoked potentials
Recipient
NEUROTYPE INC.
Award Amount
$870,345.00
Ceiling
$870,345.00
Awarded
May 14, 2026
Identifier
RFA-DA-23-021
Award for developing a device to monitor drug craving in opioid use disorder patients using EEG technology, including clinical trials for FDA approval.
Description
This project involves creating a regulated device to monitor Cue-Induced drug craving in opioid use disorder patients, integrating EEG technology, and conducting clinical trials to demonstrate safety and efficacy for FDA approval.